NASDAQ$VKTX
Viking Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Viking Therapeutics reported Q1 2025 with no product revenue and a net loss of $45.6M.
The company had no revenue for the quarter ended March 31, 2025, as clinical-stage programs advanced. Net loss was $45.6 million as R&D spending increased on obesity and NASH candidates. Cash of $851.9 million supports operations beyond the next twelve months per MD&A.
- No commercial revenue; pre-revenue clinical biotech.
- Net loss $45.6M on higher R&D for VK2735 and pipeline.
- Interest income partially offset operating loss.
- Trial readouts and financing needs drive the outlook.
Headline financials
Revenue & EPS history
Viking Therapeutics · Revenue · Quarterly
$0
Forward guidance
Clinical-stage outlook driven by trial milestones and R&D spend.
Tailwinds
- Strong cash balance funds pipeline advancement.
- Obesity and metabolic programs address large markets.
Headwinds
- No product revenue until regulatory approval.
- Trial outcomes and competition affect funding needs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+1.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+10.3%
Avg return
30 days after
48%
21 / 44 earnings
Positive
+25.5%
Q2 2024
Best reaction
-12.1%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | -0.1% | +4.4% | |
| Q4 2025 | +6.8% | +6.7% | +24.8% | |
| Q3 2025 | +8.1% | +11.2% | +9.0% | |
| Q1 2025 | -0.5% | +8.3% | +4.6% | |
| Q4 2024 | -6.1% | -10.6% | -13.1% | |
| Q3 2024 | +18.0% | +20.1% | -15.2% | |
| Q2 2024 | +25.5% | +18.8% | +25.4% | |
| Q1 2024 | +6.1% | +16.2% | -3.4% | |
| Q4 2023 | +17.4% | +28.9% | +191.7% | |
| Q3 2023 | -9.2% | -10.0% | +15.3% | |
| Q2 2023 | -5.4% | +0.1% | -6.0% | |
| Q1 2023 | -1.4% | +11.3% | +7.2% | |
| Q4 2022 | +7.2% | +6.7% | +3.9% | |
| Q3 2022 | -1.5% | +0.2% | -2.0% | |
| Q2 2022 | -2.1% | -12.0% | +2.1% | |
| Q1 2022 | +5.7% | +10.5% | +1.7% | |
| Q4 2021 | +12.8% | +4.5% | -11.4% | |
| Q3 2021 | +5.5% | +3.0% | -22.9% | |
| Q2 2021 | +6.5% | +6.5% | +9.5% | |
| Q1 2021 | +0.5% | +0.3% | -15.9% | |
| Q4 2020 | -11.1% | -15.2% | -25.7% | |
| Q3 2020 | +0.2% | +0.4% | +19.9% | |
| Q2 2020 | +14.4% | +10.8% | +3.6% | |
| Q1 2020 | -12.1% | +7.9% | +15.3% | |
| Q4 2019 | -6.4% | -4.4% | -28.9% | |
| Q3 2019 | +12.0% | +19.8% | +6.0% | |
| Q2 2019 | -5.9% | -6.0% | -9.6% | |
| Q1 2019 | +7.9% | +6.2% | -1.9% | |
| Q4 2018 | -3.3% | +6.5% | +17.2% | |
| Q3 2018 | -4.4% | -14.6% | -29.9% | |
| Q2 2018 | -0.2% | +3.0% | +8.6% | |
| Q1 2018 | +9.8% | +10.0% | +133.4% | |
| Q4 2017 | -7.1% | -0.2% | -27.2% | |
| Q3 2017 | -5.2% | +16.9% | +76.6% | |
| Q2 2017 | +6.3% | +8.4% | +21.1% | |
| Q1 2017 | -5.1% | -9.4% | -8.7% | |
| Q4 2016 | -7.8% | -7.8% | +6.2% | |
| Q3 2016 | +10.0% | +18.0% | +12.0% | |
| Q2 2016 | -3.8% | -3.8% | +2.3% | |
| Q1 2016 | +5.9% | — | — | |
| Q4 2015 | -10.7% | — | — | |
| Q3 2015 | -9.9% | — | — | |
| Q2 2015 | +5.7% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro